NDA 218201 · Sebela Womens Hlth
Miudella
Copper · Intrauterine · Copper-containing Intrauterine Device
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Feb 24, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
158
26 Phase 3, 16 recruiting
FAERS reports
737
493 serious, 40 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complications [see Warnings and Precautions (5.1) ] . Proper training prior to first use of Miudella can minimize the risk of improper Miudella insertion [see Warnings and Precautions (5.1) ]. Miudella is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Miudella REMS program to ensure healthcare providers are trained on the proper insertion of Miudella prior to first use [see Warnings and Precautions (5.2) ]. WARNING: RISK OF COMPLICATIONS DUE TO IMPROPER INSERTION Improper insertion of intrauterine systems, including Miudella, increases the risk of complications [see Warnings and Precautions (5.1) ]. Proper training prior to first use of Miudella can minimize the risk of improper...
What it is approved for
From the label in effect Oct 7, 2026.
Miudella is indicated for prevention of pregnancy in females of reproductive potential for up to 3 years. Miudella is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 3 years.( 1 )
Mechanism: Copper continuously released into the uterine cavity contributes to the contraceptive effectiveness of Miudella. Mechanism(s) by which copper enhances contraceptive efficacy include interference with sperm transport and fertilization of an egg.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MIUDELLA · COPPER N/A · SYSTEM, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Copper" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
- Evaluation of Efficacy, Safety and Tolerability of VeraCept IUSPivotal-lookingActive, not recruiting
Sebela Women's Health Inc.Industry
NCT03633799 · 1,620 participants · Start Aug 22, 2018 · Primary completion Sep 22, 2022
Drug: VeraCept · For: Women at Risk for Pregnancy
Sites: Scottsdale, Arizona; Tucson, Arizona; Berkeley, California · 41 sites in all
- LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult WomenActive, not recruiting
Insud PharmaIndustry
NCT05303636 · 1,536 participants · Start Mar 28, 2022 · Primary completion Dec 2027
Drug: drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet · For: Change in Bone Mineral Density; Bone Loss
Sites: Phoenix, Arizona; Aurora, Colorado; Boynton Beach, Florida · 37 sites in all
- Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria ComponentPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00680732 · 1,370 participants · Start Jun 2003 · Primary completion Oct 2006
Drug: Chloroquine (CQ); Sulphadoxyne-pyrimethamine (SP) · For: Malaria; Malaria in Pregnancy
Sites: Bobo-Dioulasso, Burkina Faso
- Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGardPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT03124160 · 1,105 participants · Start May 26, 2017 · Primary completion Jun 6, 2022
Drug: Mona Lisa® NT Cu380 Mini; ParaGard® TCu380A · For: Healthy Women; Female Contraception
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 16 sites in all
- Long-Acting Reversible ContraceptionPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01299116 · 916 participants · Start Dec 2011 · Primary completion Jun 2016
Drug: DMPA; oral contraceptives and 3 more · For: Contraception
Sites: Chapel Hill, North Carolina
- Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche FormationPivotal-lookingCompleted
Benha UniversityAcademic, hospital or other
NCT07264933 · 750 participants · Start Feb 12, 2025 · Primary completion Aug 5, 2025
Drug: progesterone-only pills · For: Scar Niche; Myometrial Remodeling; Contraceptive Device; Complications and 1 more
Sites: Banhā, Egypt
- RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for ECPivotal-lookingCompleted
University of UtahAcademic, hospital or other
NCT02175030 · 711 participants · Start Aug 2016 · Primary completion Feb 2020
Drug: Copper IUD; Levonorgestrel IUD · For: Contraception
Sites: Logan, Utah; Ogden, Utah; Orem, Utah · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue75
- off label use74
- headache64
- nausea64
- pain62
- diarrhoea61
- drug ineffective52
- weight decreased49
- malaise43
- abdominal pain40
- anaemia36
- dizziness36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 14 |
| 2012 | 13 |
| 2013 | 21 |
| 2014 | 21 |
| 2015 | 32 |
| 2016 | 60 |
| 2017 | 23 |
| 2018 | 45 |
| 2019 | 56 |
| 2020 | 52 |
| 2021 | 63 |
| 2022 | 69 |
| 2023 | 62 |
| 2024 | 63 |
| 2025 | 67 |
| 2026 | 48 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
Moray KV, Chaurasia H, Sachin O, et al. · Reprod Health 2021 · Meta-Analysis, Systematic Review
- Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis.
Chowdhury R, Ramond A, O'Keeffe LM, et al. · BMJ 2018 · Meta-Analysis, Systematic Review
- Micronutrient deficiencies in patients with celiac disease: A systematic review and meta-analysis.
Lamjadli S, Oujamaa I, Souli I, et al. · Int J Immunopathol Pharmacol 2025 · Systematic Review, Meta-Analysis
- Interventions for treating phosphorus burns.
Barqouni L, Abu Shaaban N, Elessi K · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Interventions for emergency contraception.
Cheng L, Gülmezoglu AM, Piaggio G, et al. · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Interventions for treating phosphorus burns.
Barqouni L, Abu Shaaban N, Elessi K · Cochrane Database Syst Rev 2012 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Sebela Womens Hlth
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.